Menu
Washingtoner
  • Home
  • Business
  • Transportation
  • Aerospace
  • Boeing
  • Kelly Ortberg
  • Health
  • Technology
  • Manufacturing
Washingtoner

Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
Washingtoner/10175938

Trending...
  • Spokane: City Construction Projects Traffic Impacts Next Week
  • Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum
  • Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. ("Kubota Vision"), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride ("emixustat") in patients with macular atrophy secondary to Stargardt disease.

The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 clinical study in which subjects were randomly assigned to emixustat 10 mg or placebo (2:1 ratio) once daily for 24 months. The target total number of subjects was 162; however, due to high interest in the study, a total of 194 subjects were enrolled in this study across 29 sites in 11 countries worldwide. The last patient has completed the study. The primary objective of this study is to determine if emixustat reduces the rate of macular atrophy progression, in comparison to placebo, in subjects with Stargardt disease. Secondary objectives include assessing changes in visual function parameters such as BCVA (best-corrected visual acuity) letter score and reading speed. The database of this study will be locked in the third quarter 2022.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, "Despite Stargardt being a rare disease, we were able to enroll more patients than originally planned and feel grateful that the patients trusted our drug with great expectation and continued taking the drug for two years during the pandemic. We would like to sincerely thank all of the participants and their families for their cooperation and are very pleased that the long-term, large-scale clinical trial has been successfully completed. We are also looking forward to receiving the results of the trial in the coming months."

The FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) granted orphan drug designation to emixustat for the treatment of Stargardt disease. (See January 5, 2017 press release titled "Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease" and June 9, 2019 press release titled "Acucela Receives Orphan Designation from the EMA for Emixustat for the Treatment of Stargardt Disease")

More on Washingtoner
  • UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
  • $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
  • Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
  • Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
  • QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI

About Stargardt Disease

Stargardt disease is a rare, genetically inherited disease that directly affects the retina of the eye, often resulting in the slow progression of vision loss in children. It may also be referred to as Stargardt macular dystrophy or juvenile macular degeneration and affects approximately 1 in 8,000 - 10,000 individuals worldwide.*1 The most common form of the disease is caused by a genetic mutation of the ABCA4 gene leading to the accumulation of toxic vitamin A byproducts (primarily A2E) in the retina, which results in the gradual deterioration of photoreceptors and vision. Symptoms of Stargardt disease typically appear during childhood or adolescence, but in some cases difficulty with eyesight and vision loss may not be identified until later in life.

Stargardt disease affects less than 150,000 patients in total in the U.S., Europe and Japan where it is recognized as an orphan disease. Currently, there are no known therapies that slow the advance of the disease, and it is recognized as a serious unmet medical need.

*1 Facts About Stargardt Disease, National Eye Institute. https://nei.nih.gov/health/stargardt/star_facts, accessed on 14 September 2018.

About Emixustat Hydrochloride

Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process. Slowing the visual cycle reduces the availability of vitamin A derivatives (11-cis- and all-trans-retinal) to form precursors of toxic A2E and related compounds. In addition, reducing the availability of 11-cis-retinal decreases retinal metabolic demands under dark conditions. Emixustat when delivered orally was found to be generally well tolerated in human clinical studies with delayed dark adaptation being the most common adverse event. Kubota Vision is exploring emixustat's potential to stop or slow the progression of vision loss in patients diagnosed with Stargardt disease in an ongoing clinical study.

More on Washingtoner
  • New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
  • Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
  • GlobalBoost (BSTY) Surges 30% Ahead of Biconomy Exchange Listing
  • City of Spokane Tourism and Cultural Investment Committee Wins State Tourism Award
  • Oom Yung Doe Traditional Martial Arts Tournament

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements: https://www.kubotaholdings.co.jp/en/1/index.html

"Kubota Vision", the Kubota Vision logo and "Kubota" are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Contacts

Media and Investor Relations Contact:

Mikio Fukai
Corporate Planning Division
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • REPRESENTATION REVOLUTION: FLM TV Network Launches as America's First Truly Diverse Broadcast Network
  • GlobalBoost Announces Listing on Biconomy Exchange Expanding Accessibility of Decentralized Payments
  • MetroWest wellness: Holliston farmhouse spa unveils Centerpoint Studio
  • Cancer Survivor Roslyn Franken Marks 30-Year Milestone with Empowering Gift for Women Survivors
  • Spokane: Overnight shooting leaves one man dead; MCU Detectives working to find suspect, motive
  • ENERGY33 Successfully Completes Second Engineering & Construction Management Contract for a 27MW STX Cogeneration Power Plant in Honduras
  • Florida International University: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
  • CCHR: VA's Psychiatric Treatments Betray Veterans, Fuel Suicide and Death
  • Integris Composites Named Armor Partner for U.S. Army's XM30 Combat Vehicle
  • Jaipur Countryside, 4-Star Comfort: $199 for Two— All-Inclusive with Meals + Transfers at Heritage Hotel Savista
  • Probate Shepherd® Announces a New Member Probate Attorney in Fort Worth, TX
  • Phinge Announces "Test the Waters" Campaign for Potential Regulation A+ Offering: Home of Netverse Verified AI & Patented App-less Technology Platform
  • RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
  • Probate Shepherd® Announces a New Member Probate Attorney in Sugar Land, TX
  • Property Care Northwest Expands Redmond Landscaping Services with Artificial Turf Installation
  • Live Good Leads with Love: Creating Opportunity, Protecting the Vulnerable and Inspiring Hope
  • Probate Shepherd® Announces a New Member Probate Attorney in The Woodlands, TX
  • Probate Shepherd® Announces a New Member Probate Attorney in Conroe, TX
  • Taraji P. Henson's Boris Lawrence Henson Foundation (BLHF) Announce 5th Annual Can We Talk? Arts & Wellness Summit and "i AM The Table Benefit Brunch
  • Spokane: City Construction Projects Traffic Impacts Next Week
_catLbl0 _catLbl1

Popular on Washingtoner

  • New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle' - 896
  • City of Tacoma to Host ‘Access to Capital’ Panel Discussion and Q&A for Local Entrepreneurs on October 27 - 185
  • New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
  • Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
  • City of Spokane Faces New Budget Deficit Amid Slowing National Economy, External Pressures
  • Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
  • Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
  • 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
  • Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
  • NKSCX Responds to "Coordinated Smear Campaign" as Anonymous Critics Emerge Following Regulatory Milestones

Similar on Washingtoner

  • OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
  • Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
  • New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
  • NASA Agreements, New Ocean Exploration Applications Added to Partnerships with Defiant Space Corp and Emtel Energy USA for Solar Tech Leader: $ASTI
  • Chic and Secure: The Blue Luna Debuts Stylish Keychains with Purpose
  • $500,000 in Stock Dividend for Shareholders in 2025 Sweetens The Pot on Success of Becoming Debt Free with No Convertible Notes or Warrants for $IQST
  • Aissist.io Launches Hybrid AI Workforce to Solve AI Pilot Failure for Customer Support Automation
  • RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
  • Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute